Effect of etoposide on the pharmacokinetics of methotrexate in vivo

Krisztina Paál, János Horváth, Csilla Csáki, Tamás Ferencz, D. Schuler, Joseph D. Borsi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The effect of etoposide on the pharmakokinetics of methotrexate (MTX) was examined in vivo. High-dose (5 g/m2/24 h) MTX therapy was combined with two etoposide (100 mg/m2/1 h) infusions as a part of the medulloblastoma protocol developed in our department. Vepesid therapy was administered in two different schedules. The first group of patients received etoposide immediately before and at the end (24 h) of MTX treatment. The second group was treated with etoposide at 24 and at 48 h after starting MTX infusion. In this latter group both treatment-related grade III and grade IV toxicity developed more frequently than in the first group (58.6 versus 29.2%, for grade 3 toxicity p = 0.019, for grade 4 toxic signs p = 0.040, respectively). We observed that after the second dose of etoposide given at 48 h (second group) both total and unbound serum MTX levels (determined by high-performance liquid chromatography) were elevated by 53-109 and 26-65%, respectively, by the third hour after completion of Vepesid infusion. This effect was detectable for 6 h. All the liver and kidney functions of the patients were within the normal range. These results suggest the possibility of partial recirculation of extra/intracellular MTX into the blood after etoposide administration. Based on these results, the therapeutic protocol has been modified, and Vepesid is given prior to and at the end (24 h) of high-dose MTX treatment. Under these conditions only a slight decrease of MTX elimination has been detected between 25 and 28 h. These results emphasize the role of possible schedule-dependent interactions of cytostatic drugs.

Original languageEnglish
Pages (from-to)765-772
Number of pages8
JournalAnti-Cancer Drugs
Volume9
Issue number9
DOIs
Publication statusPublished - 1998

Fingerprint

Etoposide
Methotrexate
Pharmacokinetics
Appointments and Schedules
Therapeutics
Medulloblastoma
Poisons
Cytostatic Agents
Reference Values
High Pressure Liquid Chromatography
Kidney
Liver
Serum

Keywords

  • Brain tumor
  • Children
  • Etoposide
  • Methotrexate
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Effect of etoposide on the pharmacokinetics of methotrexate in vivo. / Paál, Krisztina; Horváth, János; Csáki, Csilla; Ferencz, Tamás; Schuler, D.; Borsi, Joseph D.

In: Anti-Cancer Drugs, Vol. 9, No. 9, 1998, p. 765-772.

Research output: Contribution to journalArticle

Paál, K, Horváth, J, Csáki, C, Ferencz, T, Schuler, D & Borsi, JD 1998, 'Effect of etoposide on the pharmacokinetics of methotrexate in vivo', Anti-Cancer Drugs, vol. 9, no. 9, pp. 765-772. https://doi.org/10.1097/00001813-199810000-00004
Paál, Krisztina ; Horváth, János ; Csáki, Csilla ; Ferencz, Tamás ; Schuler, D. ; Borsi, Joseph D. / Effect of etoposide on the pharmacokinetics of methotrexate in vivo. In: Anti-Cancer Drugs. 1998 ; Vol. 9, No. 9. pp. 765-772.
@article{ff5b531dc2b14897a33dc0395363d450,
title = "Effect of etoposide on the pharmacokinetics of methotrexate in vivo",
abstract = "The effect of etoposide on the pharmakokinetics of methotrexate (MTX) was examined in vivo. High-dose (5 g/m2/24 h) MTX therapy was combined with two etoposide (100 mg/m2/1 h) infusions as a part of the medulloblastoma protocol developed in our department. Vepesid therapy was administered in two different schedules. The first group of patients received etoposide immediately before and at the end (24 h) of MTX treatment. The second group was treated with etoposide at 24 and at 48 h after starting MTX infusion. In this latter group both treatment-related grade III and grade IV toxicity developed more frequently than in the first group (58.6 versus 29.2{\%}, for grade 3 toxicity p = 0.019, for grade 4 toxic signs p = 0.040, respectively). We observed that after the second dose of etoposide given at 48 h (second group) both total and unbound serum MTX levels (determined by high-performance liquid chromatography) were elevated by 53-109 and 26-65{\%}, respectively, by the third hour after completion of Vepesid infusion. This effect was detectable for 6 h. All the liver and kidney functions of the patients were within the normal range. These results suggest the possibility of partial recirculation of extra/intracellular MTX into the blood after etoposide administration. Based on these results, the therapeutic protocol has been modified, and Vepesid is given prior to and at the end (24 h) of high-dose MTX treatment. Under these conditions only a slight decrease of MTX elimination has been detected between 25 and 28 h. These results emphasize the role of possible schedule-dependent interactions of cytostatic drugs.",
keywords = "Brain tumor, Children, Etoposide, Methotrexate, Pharmacokinetics",
author = "Krisztina Pa{\'a}l and J{\'a}nos Horv{\'a}th and Csilla Cs{\'a}ki and Tam{\'a}s Ferencz and D. Schuler and Borsi, {Joseph D.}",
year = "1998",
doi = "10.1097/00001813-199810000-00004",
language = "English",
volume = "9",
pages = "765--772",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Effect of etoposide on the pharmacokinetics of methotrexate in vivo

AU - Paál, Krisztina

AU - Horváth, János

AU - Csáki, Csilla

AU - Ferencz, Tamás

AU - Schuler, D.

AU - Borsi, Joseph D.

PY - 1998

Y1 - 1998

N2 - The effect of etoposide on the pharmakokinetics of methotrexate (MTX) was examined in vivo. High-dose (5 g/m2/24 h) MTX therapy was combined with two etoposide (100 mg/m2/1 h) infusions as a part of the medulloblastoma protocol developed in our department. Vepesid therapy was administered in two different schedules. The first group of patients received etoposide immediately before and at the end (24 h) of MTX treatment. The second group was treated with etoposide at 24 and at 48 h after starting MTX infusion. In this latter group both treatment-related grade III and grade IV toxicity developed more frequently than in the first group (58.6 versus 29.2%, for grade 3 toxicity p = 0.019, for grade 4 toxic signs p = 0.040, respectively). We observed that after the second dose of etoposide given at 48 h (second group) both total and unbound serum MTX levels (determined by high-performance liquid chromatography) were elevated by 53-109 and 26-65%, respectively, by the third hour after completion of Vepesid infusion. This effect was detectable for 6 h. All the liver and kidney functions of the patients were within the normal range. These results suggest the possibility of partial recirculation of extra/intracellular MTX into the blood after etoposide administration. Based on these results, the therapeutic protocol has been modified, and Vepesid is given prior to and at the end (24 h) of high-dose MTX treatment. Under these conditions only a slight decrease of MTX elimination has been detected between 25 and 28 h. These results emphasize the role of possible schedule-dependent interactions of cytostatic drugs.

AB - The effect of etoposide on the pharmakokinetics of methotrexate (MTX) was examined in vivo. High-dose (5 g/m2/24 h) MTX therapy was combined with two etoposide (100 mg/m2/1 h) infusions as a part of the medulloblastoma protocol developed in our department. Vepesid therapy was administered in two different schedules. The first group of patients received etoposide immediately before and at the end (24 h) of MTX treatment. The second group was treated with etoposide at 24 and at 48 h after starting MTX infusion. In this latter group both treatment-related grade III and grade IV toxicity developed more frequently than in the first group (58.6 versus 29.2%, for grade 3 toxicity p = 0.019, for grade 4 toxic signs p = 0.040, respectively). We observed that after the second dose of etoposide given at 48 h (second group) both total and unbound serum MTX levels (determined by high-performance liquid chromatography) were elevated by 53-109 and 26-65%, respectively, by the third hour after completion of Vepesid infusion. This effect was detectable for 6 h. All the liver and kidney functions of the patients were within the normal range. These results suggest the possibility of partial recirculation of extra/intracellular MTX into the blood after etoposide administration. Based on these results, the therapeutic protocol has been modified, and Vepesid is given prior to and at the end (24 h) of high-dose MTX treatment. Under these conditions only a slight decrease of MTX elimination has been detected between 25 and 28 h. These results emphasize the role of possible schedule-dependent interactions of cytostatic drugs.

KW - Brain tumor

KW - Children

KW - Etoposide

KW - Methotrexate

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0031790654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031790654&partnerID=8YFLogxK

U2 - 10.1097/00001813-199810000-00004

DO - 10.1097/00001813-199810000-00004

M3 - Article

C2 - 9840721

AN - SCOPUS:0031790654

VL - 9

SP - 765

EP - 772

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -